What is the address of PHARMIMPULSE?

The registered office of PHARMIMPULSE is located at Rue de la Bachée 86, 1380 Lasne.

Is PHARMIMPULSE still active?

Yes. According to the CBE (30 October 2026) PHARMIMPULSE is active, legal situation “Normale toestand”, started on 11 August 2015.

Is PHARMIMPULSE registered on Peppol?

Yes, PHARMIMPULSE is registered on the Peppol network with ID 0208:0634979024.

What is the enterprise number of PHARMIMPULSE?

The enterprise number of PHARMIMPULSE is BE0634979024.

When was PHARMIMPULSE founded?

PHARMIMPULSE was founded on 11 August 2015.

Who are the directors of PHARMIMPULSE?

According to the 2025 annual accounts, the directors of PHARMIMPULSE are: PAUL RANSART.

Is PHARMIMPULSE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 August 2015; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMIMPULSE make in 2025?

PHARMIMPULSE recorded a loss after taxes of € 81,057 in financial year 2025.

What is the revenue of PHARMIMPULSE?

As a small company, PHARMIMPULSE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 171,172.

How much does an employee at PHARMIMPULSE earn?

The average wage cost per full-time employee at PHARMIMPULSE was € 46,600 in 2021: staff costs of € 521,475 for 11.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

PHARMIMPULSE - Lasne - BE0634979024

Q: What does PHARMIMPULSE do?

PHARMIMPULSE is registered with the CBE as active in: Administratieve en ondersteunende activiteiten ten behoeve van kantoren. General partnership, started on 11 August 2015, 1 establishment.

Dossier PHARMIMPULSE, printed on 30 October 2026 from databakkes.be/en/0634979024/pharmimpulse. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 1 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 49 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

PHARMIMPULSE from Lasne, company number BE0634979024, closed financial year 2025 with a result of € -81,057 after tax. For that financial year PHARMIMPULSE recorded a gross margin of € 171,172 and equity of € -77,307. Compared with financial year 2024, the result moved from € 0 to € -81,057. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 27, 2026.

What it is worth Caution

€ -77,307

▼ € 81,057 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -81,057

▼ still € 0 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 3,175

▼ 79% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -81,057.

People and assets in 2025

Wage cost

€ 240,771

▼ 71% vs 2024

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 408

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 14,104

▼ 38% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 14,775

▼ 90% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 72,776

▼ 38% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2024	2025	Change 2024 → 2025
Gross margin	€ 522,423 Gross margin 2021: € 522,423 First fiscal year in the series	€ 715,651 Gross margin 2022: € 715,651 ▲ 37% vs 2021 (€ 522,423) Favourable step	€ 842,528 Gross margin 2024: € 842,528 ▲ 18% vs 2022 (€ 715,651) Favourable step	€ 171,172 Gross margin 2025: € 171,172 ▼ 80% vs 2024 (€ 842,528) Unfavourable step	▼ 80%
Profit after taxes	€ 0 Profit after taxes 2021: € 0 First fiscal year in the series	€ 0 Profit after taxes 2022: € 0 Unchanged (€ 0) Unchanged	€ 0 Profit after taxes 2024: € 0 Unchanged (€ 0) Unchanged	€ -81,057 Profit after taxes 2025: € -81,057 Unchanged (€ 0) Unfavourable step
Equity	€ 3,750 Equity 2021: € 3,750 First fiscal year in the series	€ 3,750 Equity 2022: € 3,750 Unchanged (€ 3,750) Unchanged	€ 3,750 Equity 2024: € 3,750 Unchanged (€ 3,750) Unchanged	€ -77,307 Equity 2025: € -77,307 ▼ € 81,057 vs 2024 (€ 3,750) Unfavourable step	▼ € 81,057
Total debts	€ 144,862 Total debts 2021: € 144,862 First fiscal year in the series	€ 216,214 Total debts 2022: € 216,214 ▲ 49% vs 2021 (€ 144,862) Unfavourable step	€ 380,611 Total debts 2024: € 380,611 ▲ 76% vs 2022 (€ 216,214) Unfavourable step	€ 187,007 Total debts 2025: € 187,007 ▼ 51% vs 2024 (€ 380,611) Favourable step	▼ 51%
Cash	€ 22,837 Cash 2021: € 22,837 First fiscal year in the series	€ 24,352 Cash 2022: € 24,352 ▲ 7% vs 2021 (€ 22,837) Favourable step	€ 15,050 Cash 2024: € 15,050 ▼ 38% vs 2022 (€ 24,352) Unfavourable step	€ 3,175 Cash 2025: € 3,175 ▼ 79% vs 2024 (€ 15,050) Unfavourable step	▼ 79%
Retained profit	€ 0 Retained profit 2021: € 0 First fiscal year in the series	€ 0 Retained profit 2022: € 0 Unchanged (€ 0) Unchanged	€ 0 Retained profit 2024: € 0 Unchanged (€ 0) Unchanged	€ -81,057 Retained profit 2025: € -81,057 Unchanged (€ 0) Unfavourable step
Bank debt	€ 0 Bank debt 2021: € 0 First fiscal year in the series	€ 0 Bank debt 2022: € 0 Unchanged (€ 0) Unchanged	€ 22,819 Bank debt 2024: € 22,819 Unchanged (€ 0) Unfavourable step	€ 14,104 Bank debt 2025: € 14,104 ▼ 38% vs 2024 (€ 22,819) Favourable step	▼ 38%
Balance sheet total	€ 148,612 Balance sheet total 2021: € 148,612 First fiscal year in the series	€ 219,964 Balance sheet total 2022: € 219,964 ▲ 48% vs 2021 (€ 148,612) Unchanged	€ 384,361 Balance sheet total 2024: € 384,361 ▲ 75% vs 2022 (€ 219,964) Unchanged	€ 109,700 Balance sheet total 2025: € 109,700 ▼ 71% vs 2024 (€ 384,361) Unchanged	▼ 71%
Employees (FTE)	11.2 Employees (FTE) 2021: 11.2 First fiscal year in the series	-	-	-

Key figures of PHARMIMPULSE, fiscal years 2021 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMIMPULSE?

What happened at PHARMIMPULSE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 PAUL RANSART stepped down as director. NBB
Sep 27, 2026 New annual accounts for financial year 2025: loss of € 81,057. filed late Source: NBB ↗
Aug 11, 2015 New establishment in Lasne. KBO
2015 PAUL RANSART became a director. NBB
Aug 11, 2015 Start of the company according to the CBE. KBO

In short

From € 0 profit in 2021 to € 81,057 loss in 2025.

Paid € 7,924 in corporate taxes since 2021.

On average € 46,600 of value added per employee in 2021.

Original PDFs at the National Bank ↗

Management

PALATINE 100%

PHARMACIE DEFRE 6.7%

envergure invest 6.7%

The stake of PALATINE, PHARMACIE DEFRE, envergure invest comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMIMPULSE

The shares are held by PALATINE (100%), PHARMACIE DEFRE (6.7%) and envergure invest (6.7%).

Directors

According to the 2025 annual accounts

PAUL RANSART

Director

Also active at: COMPAGNIE FINANCIERE ET IMMOBILIERE DE LA DYLE, PHARMACIE de BARRY, PALATINE, LENANS, IMMOLENANS, APOGREZ, ANCIAUX, LES PHARMACIES RURALES +15 more

since 2015 · until 2027

Shareholders

PALATINE

100%

PHARMACIE DEFRE

6.7%

envergure invest

6.7%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de la Bachée 86

1380 Lasne

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

KITALPHAR

€ 45,679 gross margin · 2025

PHARMAPULSE same network

€ 889,809 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0634.979.024

VAT number

BE 0634.979.024

Registered office

Rue de la Bachée 86, 1380 Lasne

Names & denominations

PHARMIMPULSE

Enterprise type

Rechtspersoon

Legal form

General partnership

Legal situation

Normale toestand

Start date

11 August 2015

Peppol

Active · Active since 31 Dec 2025

Activities · NACE

Administratieve en ondersteunende activiteiten ten behoeve van kantoren

Activiteiten van uitzendbureaus en andere diensten in verband met personeelsvoorziening

Andere vormen van arbeidsbemiddeling

Overige zakelijke dienstverlening, neg

Diverse administratieve activiteiten ten behoeve van kantoren

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMIMPULSE

Warning lights

Financials

What happened to PHARMIMPULSE?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions